Travere Therapeutics (TVTX) News Today $26.24 +1.60 (+6.50%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wall Street ZenOctober 5 at 3:19 AM | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Stock Rating Upgraded by Wall Street ZenOctober 4 at 3:09 AM | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives $34.20 Consensus Price Target from BrokeragesOctober 4 at 2:39 AM | americanbankingnews.comTravere Therapeutics price target lowered to $35 from $45 at Evercore ISIOctober 1, 2025 | msn.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Here's WhyOctober 1, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 1, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading Down 7.6% - What's Next?September 29, 2025 | marketbeat.comCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA NephropathySeptember 26, 2025 | prnewswire.comTravere Therapeutics (NASDAQ:TVTX) Insider Elizabeth Reed Sells 10,000 SharesSeptember 25, 2025 | insidertrades.comInsider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 10,000 Shares of StockSeptember 24, 2025 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Acquired by Assenagon Asset Management S.A.September 23, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX)September 20, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to "Hold"September 20, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $25.00September 14, 2025 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Sold by AQR Capital Management LLCSeptember 14, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Shares Down 4.8% - Should You Sell?September 13, 2025 | marketbeat.comWells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | marketbeat.comWoodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTXSeptember 13, 2025 | marketbeat.comTravere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGSSeptember 12, 2025 | seekingalpha.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Here's What HappenedSeptember 12, 2025 | marketbeat.comTravere Therapeutics price target raised to $35 from $27 at Wells FargoSeptember 11, 2025 | msn.comTravere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate SubsideSeptember 11, 2025 | insidermonkey.comTravere rises as FDA says no AdCom required for Filspari label expansionSeptember 10, 2025 | msn.comTravere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug ApplicationSeptember 10, 2025 | msn.comTravere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical ResultsSeptember 10, 2025 | finance.yahoo.comTravere: No AdCom, No Problem - Targeting Big Revenues With FSGS ApprovalSeptember 10, 2025 | seekingalpha.comTraders Purchase High Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX)September 10, 2025 | marketbeat.comWhy Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year HighSeptember 10, 2025 | investors.comTravere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGSSeptember 10, 2025 | businesswire.comPolar Asset Management Partners Inc. Acquires New Position in Travere Therapeutics, Inc. $TVTXSeptember 9, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Stock Position in Travere Therapeutics, Inc. $TVTXSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Sells 163,721 Shares of Travere Therapeutics, Inc. $TVTXSeptember 8, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 8, 2025 | marketbeat.comTravere Therapeutics, Inc. (TVTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comAdage Capital Partners GP L.L.C. Acquires 1,808,098 Shares of Travere Therapeutics, Inc. $TVTXSeptember 6, 2025 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Sold by Trexquant Investment LPSeptember 6, 2025 | marketbeat.comTravere Therapeutics Shows Rising Price Performance With Jump To 92 RS RatingSeptember 6, 2025 | msn.comTravere Therapeutics, Inc. $TVTX Shares Acquired by Northern Trust CorpSeptember 6, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Travere Therapeutics (NASDAQ:TVTX)September 5, 2025 | marketbeat.comTravere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comTravere Therapeutics (NASDAQ:TVTX) Trading 5% Higher After Analyst UpgradeSeptember 4, 2025 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Bought by PDT Partners LLCSeptember 3, 2025 | marketbeat.comTravere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of MetabolismSeptember 3, 2025 | businesswire.comTravere Therapeutics, Inc. (TVTX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comArmistice Capital LLC Grows Holdings in Travere Therapeutics, Inc. $TVTXSeptember 2, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Rating Increased to Buy at Wall Street ZenSeptember 2, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TVTX FY2026 Earnings?September 2, 2025 | marketbeat.comRafferty Asset Management LLC Has $2.60 Million Stock Position in Travere Therapeutics, Inc. $TVTXSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Acquires 549,718 Shares of Travere Therapeutics, Inc. $TVTXAugust 31, 2025 | marketbeat.comWalleye Capital LLC Sells 158,092 Shares of Travere Therapeutics, Inc. $TVTXAugust 29, 2025 | marketbeat.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.400.54▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼78▲TVTX Articles Average Week Get the Latest News and Ratings for TVTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Revolution Medicines News Today Grifols News Today Rhythm Pharmaceuticals News Today Avidity Biosciences News Today Abivax News Today Legend Biotech News Today Cytokinetics News Today Nuvalent News Today Axsome Therapeutics News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Dollar’s Crashing—What Are You Doing About It?The U.S. dollar is down 10.8%—its steepest drop since 1973. As global confidence in the dollar fades, centr...Lear Capital | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
